Developing a markerless tracking method for real-time tumor motion measurement during radiation therapy
LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology
University of Sydney · NCT05184790
This study is testing a new way to track tumor movement during radiation therapy without using markers, to see if it can help doctors target the treatment more accurately for cancer patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Sydney (other) |
| Drugs / interventions | radiation |
| Locations | 4 sites (Saint Leonards, New South Wales and 3 other locations) |
| Trial ID | NCT05184790 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a whole-of-body markerless tracking method to measure tumor and organ motion during radiation therapy. By utilizing routinely acquired patient data from 300 individuals with various cancers, the study will train, test, and validate this tracking method. The data will be processed through a clinical trial learning system that enhances the accuracy of the tracking software with each patient. The primary goal is to improve targeting accuracy in radiation therapy through advanced imaging techniques.
Who should consider this trial
Good fit: Ideal candidates are adults receiving radiation therapy for specific cancers, including brain, breast, kidney, and prostate cancers, or cardiac arrhythmias.
Not a fit: Patients under 18 years of age or those not receiving radiation therapy at participating centers will not benefit from this study.
Why it matters
Potential benefit: If successful, this method could significantly enhance the precision of radiation therapy, leading to better treatment outcomes for patients.
How similar studies have performed: While the approach of using markerless tracking in radiation therapy is innovative, similar studies have shown promise in improving treatment accuracy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Will receive radiation therapy for brain, breast, head and neck, kidney, liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment at a participating centre. * Will receive CT planning, and a cone beam CT scan for at least one fraction of radiation therapy. * Will receive intrafraction x-ray imaging for the liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment. As intrafraction imaging is not common standard of care for brain, breast, head and neck and kidney cancer treatments there is no requirement to have intrafraction x-ray imaging data for these anatomical sites. * Provides written informed consent. Exclusion Criteria: * Less than 18 years of age
Where this trial is running
Saint Leonards, New South Wales and 3 other locations
- Royal North Shore Hospital — Saint Leonards, New South Wales, Australia (RECRUITING)
- Princess Alexandra Hospital — Woolloongabba, Queensland, Australia (NOT_YET_RECRUITING)
- Alfred Health — Melbourne, Victoria, Australia (NOT_YET_RECRUITING)
- Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia (NOT_YET_RECRUITING)
Study contacts
- Study coordinator: Shona Silvester
- Email: shona.silvester@sydney.edu.au
- Phone: +61 2 8627 1185
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Arrhythmias, Cardiac, Breast Cancer, Prostatic Cancer, Brain Cancer, Kidney Cancer, Head and Neck Cancer, Liver Cancer, Pancreatic Cancer